A second late-stage study assessing AbbVie and Neurocrine’s experimental drug elagolix in women with uterine fibroids has met its primary endpoint.
The companies reported that the GnRH receptor antagonist, when given in combination with low-dose hormone therapy, reduced heavy menstrual bleeding in patients with the condition.
According to data from the ELARIS UF-II trial, 76.2 percent of women achieved a clinical response - defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six - compared to 10.1 percent for placebo.
The firms also noted the findings are consistent with top-line data from the ELARIS UF-I study.
"Millions of women currently diagnosed with uterine fibroids are faced with limited non-surgical options," said Dawn Carlson, vice president, general medicine development.
"The results from this study demonstrate elagolix has the potential to be an important oral treatment option for women suffering from uterine fibroids."